These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 4076509)

  • 1. Lower triglyceride production during carbohydrate-rich diets through acarbose, a glucoside hydrolase inhibitor.
    Nestel PJ; Bazelmans J; Reardon MF; Boston RC
    Diabete Metab; 1985 Oct; 11(5):316-7. PubMed ID: 4076509
    [No Abstract]   [Full Text] [Related]  

  • 2. Changes in plasma lipoprotein levels during medication with a glucoside-hydrolase inhibitor (acarbose).
    Homma Y; Irie N; Yano Y; Nakaya N; Goto Y
    Tokai J Exp Clin Med; 1982 May; 7(3):393-6. PubMed ID: 7123576
    [No Abstract]   [Full Text] [Related]  

  • 3. Long-term effect of acarbose on diurnal serum triglyceride, glucose, insulin and adipose tissue lipoprotein lipase levels in patients with primary endogenous hypertriglyceridaemia, with or without type II diabetes.
    Noyon R; Pagano Mirani-Oostdijk C; van Gent CM; Frölich M; Hillebrand I; Terpstra J
    Neth J Med; 1986; 29(5):157-64. PubMed ID: 3520362
    [No Abstract]   [Full Text] [Related]  

  • 4. Inhibition of carbohydrate-induced hypertriglyceridemia by a disaccharidase inhibitor.
    Zavaroni I; Reaven GM
    Metabolism; 1981 Apr; 30(4):417-20. PubMed ID: 7010078
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Scope and specificity of acarbose in slowing carbohydrate absorption in man.
    Jenkins DJ; Taylor RH; Goff DV; Fielden H; Misiewicz JJ; Sarson DL; Bloom SR; Alberti KG
    Diabetes; 1981 Nov; 30(11):951-4. PubMed ID: 7028548
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of acarbose on the 24-hour blood glucose profile and pattern of carbohydrate absorption.
    Taylor RH; Jenkins DJ; Barker HM; Fielden H; Goff DV; Misiewicz JJ; Lee DA; Allen HB; MacDonald G; Wallrabe H
    Diabetes Care; 1982; 5(2):92-6. PubMed ID: 6927727
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibitors of the rate of carbohydrate and lipid absorption by the intestine.
    Puls W; Krause HP; Müller L; Schutt H; Sitt R; Thomas G
    Int J Obes; 1984; 8 Suppl 1():181-90. PubMed ID: 6398805
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Effect of acarbose on intestinal disaccharidase: review of its therapeutic potential].
    Sternberg A; Wagner Y; Fireman Z
    Harefuah; 1994 May; 126(9):527-9. PubMed ID: 8034269
    [No Abstract]   [Full Text] [Related]  

  • 9. Effect of an alpha-glycosidase inhibitor on experimentally-induced obesity in mice.
    Le Marchand-Brustel Y; Rochet N; Grémeaux T; Marot I; Van Obberghen E
    Diabetologia; 1990 Jan; 33(1):24-30. PubMed ID: 2154394
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of the alpha-glucosidase inhibitor, acarbose, on disaccharide splitting enzymes in human dental plaque.
    Fiehn NE; Moe D
    Scand J Dent Res; 1982 Apr; 90(2):124-30. PubMed ID: 6803351
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Medical use of alpha-glycosidase inhibitors.
    Erkelens DW
    Neth J Med; 1986; 29(5):155-6. PubMed ID: 3713938
    [No Abstract]   [Full Text] [Related]  

  • 12. Acarbose is a competitive inhibitor of mammalian lysosomal acid alpha-D-glucosidases.
    Calder PC; Geddes R
    Carbohydr Res; 1989 Aug; 191(1):71-8. PubMed ID: 2776140
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of a glucosidase inhibitor (acarbose, BAY g 5421) on the development of obesity and food motivated behavior in Zucker (fafa) rats.
    Vasselli JR; Haraczkiewicz E; Maggio CA; Greenwood MR
    Pharmacol Biochem Behav; 1983 Jul; 19(1):85-95. PubMed ID: 6622510
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of acarbose on serum lipoproteins in healthy individuals during prolonged administration of a fiber-free formula diet.
    Walter-Sack IE; Wolfram G; Zöllner N
    Ann Nutr Metab; 1989; 33(2):100-7. PubMed ID: 2554784
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Low-fat, high-carbohydrate diets and atherogenic risk.
    Baum CL; Brown M
    Nutr Rev; 2000 May; 58(5):148-51. PubMed ID: 10860395
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of acarbose (BAY-g-5421) on expression of noninsulin-dependent diabetes mellitus in sucrose-fed SHR/N-corpulent rats.
    Carswell N; Michaelis OE; Prather ES
    J Nutr; 1989 Mar; 119(3):388-94. PubMed ID: 2646401
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment of non-insulin dependent diabetic adults with a new glycoside hydrolase inhibitor (Bay g 5421).
    Sailer D; Röder G
    Arzneimittelforschung; 1980; 30(12):2182-5. PubMed ID: 7194082
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The regulation of lipogenesis in vivo in the lactating mammary gland of the rat during the starved-refed transition. Studies wtih acarbose, a glucosidase inhibitor.
    Mercer SW; Williamson DH
    Biochem J; 1987 Feb; 242(1):235-43. PubMed ID: 2954538
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Heterogeneity of VLDL triglyceride production by the liver and intestine.
    Steiner G; Ilse WK
    Can J Biochem; 1981 Aug; 59(8):637-41. PubMed ID: 7296346
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reduction of carbohydrate-induced hypertriglyceridemia in (fa,fa) "Zucker" rats by the alpha-glucosidase inhibitor acarbose (BAY g 5421).
    Krause HP; Keup U; Thomas G; Puls W
    Metabolism; 1982 Jul; 31(7):710-4. PubMed ID: 7045575
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.